Program
inavolisib
Also written as “Inavolisib”, “Inavolisib (Dose #1)” and “Inavolisib (Dose #2)”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Neoplasms · Prostatic Neoplasms · Neoplasm Metastasis, led by Hoffmann-La Roche.
Drug pageInavolisib: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 2017 open or running | phase 3since Dec 2, 2019 | Dec 22, 2016 | Dec 31, 2026phase 1 · NCT03006172 |
Also a collaborator on its studies: Gilead Sciences and Pfizer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Dec 22, 2016 to Nov 12, 2020.
- Dec 9, 2019Named inavolisibINNProposed as its International Nonproprietary Name in WHO's List 122
- Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
- Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
- Jun 11, 2021Phase 1 study in Colorectal NeoplasmsNCT04929223 · 542 planned · United States, Australia, Canada and more
- Dec 2, 2022Phase 3 study in Breast NeoplasmsNCT05646862 · 420 planned · United States, Argentina, Australia and more
- May 1, 20232 phase 3 studiesNCT05862285, NCT05894239
- Jul 4, 2024Phase 1 study in PIK3CA-Mutated CancersNCT06496568 · 30 enrolled · United States, Canada, South Korea
- Jan 14, 2025Phase 3 study in Breast NeoplasmsNCT06790693 · 450 planned · United States, Argentina, Australia and more
- Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
- Aug 20, 2025Phase 1 study in Hepatic ImpairmentNCT07144111 · 27 enrolled · United States
- Dec 11, 2025Phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT07287150 · 100 planned · United States, Australia, Brazil and more
- Jan 6, 20262 phase 2 studiesNCT07323576, NCT07368998
- Feb 6, 2026Phase 2 study in Breast NeoplasmsNCT07405801 · 80 planned · United States, Argentina, Brazil and more
- Jul 20, 2026Phase 2 study in Breast NeoplasmsNCT07748208 · 40 planned · United States, Puerto Rico
- Nov 13, 2026Primary completion moved from 2026-12-31 to 2027-05-03Date moved laterphase 3 · +4 months · NCT05894239
Ahead
- Nov 13, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05646862
- Dec 31, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT03006172
- May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05894239
- Jul 21, 2027Primary completion: phase 1 study in PIK3CA-Mutated CancersNCT06496568
TargetBeta
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07748208Breast Neoplasms · United States, Puerto Rico | 2 | Recruiting | Jun 15, 2029 | 40 |
| NCT07405801Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Dec 19, 2028 | 80 |
| NCT07368998Breast Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Oct 31, 2028 | 80 |
| NCT07323576Colorectal Neoplasms | 2 | Withdrawn | Mar 1, 2029 | 0 |
| NCT07287150Metastatic Castration-Resistant Prostate Cancer · United States, Australia, Brazil and more | 2 | Recruiting | Mar 31, 2028 | 100 |
| NCT07144111Hepatic Impairment · United States | 1 | Completed | Oct 13, 2026 | 27 |
| NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Jul 31, 2027 | 120 |
| NCT06790693Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jan 31, 2032 | 450 |
| NCT06496568PIK3CA-Mutated Cancers · United States, Canada, South Korea | 1 | Active, not recruiting | Jul 21, 2027 | 30 |
| NCT05894239Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | May 3, 2027 | 230 |
| NCT05862285Neoplasms · Belgium, Canada, China and more | 3 | Recruiting | Mar 1, 2033 | 200 |
| NCT05646862Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Nov 13, 2026 | 420 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Aug 31, 2030 | 542 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 28, 2028 | 176 |
| NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more | 2 | Recruiting | May 30, 2029 | 316 |
| NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States | 2 | Completed | Dec 4, 2023 | 252 |
| NCT04589845Solid Tumors · United States, Australia, Belgium and more | 2 | Active, not recruiting | Sep 25, 2032 | 920 |
| NCT04191499Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 29, 2023 | 325 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Sep 30, 2030 | 1,132 |
| NCT03006172Breast Neoplasms · United States, Canada, France and more | 1 | Active, not recruiting | Dec 31, 2026 | 200 |
How it is read
Names in the registry
- “Inavolisib”, 20 entries
- “Inavolisib (Dose #1)”, 1 entry
- “Inavolisib (Dose #2)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Colorectal Neoplasms, 2 studies
- Neoplasms, 1 study
- Prostatic Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.